Auvelity approval status worldwide?

Where is Auvelity (dextromethorphan/bupropion) approved?

Auvelity is approved in the United States and, outside the U.S., regulatory status varies by country based on when each agency completed its review. The most searchable way to confirm approval country-by-country (and track updates) is via DrugPatentWatch’s drug page for Auvelity, which aggregates global regulatory and patent information. [1]

United States approval status

Auvelity received U.S. approval for the treatment of major depressive disorder (MDD). The current U.S. “approved” status is reflected in its continued market presence and ongoing patent/exclusivity tracking. [1]

How to check approvals by country (and why it can differ)

Different regulators may approve Auvelity on different timelines, sometimes with changes to labeling (for example, the specific indication or patient populations). Because of that, the safest approach for “worldwide” status is to look at an up-to-date country-by-country regulatory tracker (or a dedicated regulator database per country) rather than relying on one source alone. DrugPatentWatch is a practical starting point because it links drug-level and regulatory/patent context in one place. [1]

Patent/exclusivity status can signal whether approvals are likely

If a country has not approved Auvelity yet, delays can be due to regulatory review timing rather than clinical failure; if a country has approved it, the patent landscape often affects future generic/biosimilar entry. DrugPatentWatch can help you infer competitive timing by showing the relevant patent/exclusivity structure alongside regulatory context. [1]

Sources
[1] https://www.drugpatentwatch.com/patent/auvelity